IMS must sell two business lines to buy competitor: FTC

October 2011
Modern Healthcare;10/31/2011, Vol. 41 Issue 44, p4
Trade Publication
The article focuses on the announcement by the U.S. Federal Trade Commission that the pharmaceutical market research firm IMS Health is required to sell off two business lines in order to buy a competitor in the healthcare analytics field.


Related Articles

  • FROM THE EDITOR. There Is No Free Lunch -- Really. Adler, Kenneth G. // Family Practice Management;Sep/Oct2013, Vol. 20 Issue 5, p5 

    In this article the author examines the impact of the U.S. Physician Payments Sunshine Act on physicians' relationship with the pharmaceutical industry. He describes how physicians contribute to the increasing prices of brand-name drugs by patronizing the industry's marketing programs. He also...

  • By The Numbers.  // Modern Healthcare;10/29/2012, Vol. 42 Issue 44, p32 

    A chart of the most prescribed pharmaceuticals in the U.S. in 2011 is presented which includes the drugs hydrocodone/acetaminophen, simvastatin and Lipitor.

  • 74 AN AUDIT OF NEW SEDATIVE PRESCRIBING IN ADULT INPATIENTS OVER 75 YEARS OLD AT NEWHAM UNIVERSITY HOSPITAL. Bhatia, Z.; Ellis, A.; Pickles, J. // Age & Ageing;Jun2014, Vol. 43 Issue suppl_1, pi17 

    Evidence base: Elderly people have increased sensitivity to side effects from sedation, thus increasing the risk of falls and fractures.The latest National Institute for Clinical Excellence (NICE) guidance for management of delirium no longer advocates a role for benzodiazepines as first line...

  • Relationship between Doctors' Prescribing Behavior and Pharmaceutical Promotional Tools: A Pakistani Case. ALI, Zaigham; Tauheed RANA, Muhammad Luqman; MAHMOOD, Atif; HANAN, Mian Ahmad; NOSHINA, Saleem; NAILA, Khawar // Iranian Journal of Public Health;May2015, Vol. 44 Issue 5, p709 

    A letter to the editor is presented in response to the article "Relationship between Doctors' Prescribing Behavior and Pharmaceutical Promotional Tools: A Pakistani Case," by Zaigham Ali and colleagues that was published in the previous issue.

  • NEWSBRIEFS.  // Drug Topics;7/15/2002, Vol. 146 Issue 14, pHSE6 

    Presents news briefs concerning the pharmaceutical industry in the U.S., as of July 15, 2002. Results of a study on the association between long-term treatment with the investigational drug Somavert and pituitary tumor growth in patients with acromegaly; Acquisition of Syncor International...

  • Pharma is closer than you think. McCartney, Margaret // BMJ: British Medical Journal;7/25/2015, Vol. 351 Issue 8018, ph3688 

    The article states that drug company staff have been working in general practices in Great Britain to review drug prescribing and medicines management programmes without patients' knowledge. Topics discussed include the policy of National Health Service (NHS) organisations on working with the...

  • Medicine and the Market. Kushnick, Hannah L. // AMA Journal of Ethics;Aug2015, Vol. 17 Issue 8, p727 

    An introduction is presented in which the editor discusses reports in the issue including effect of donated surgical equipment on potential bias of medical students, guidance for physicians meeting with pharmaceutical company representatives, and incentive for companies in Orphan Drug Act.

  • Underprescription of Beneficial Medicines in Older People: Causes, Consequences and Prevention. Cherubini, Antonio; Corsonello, Andrea; Lattanzio, Fabrizia // Drugs & Aging;2012, Vol. 29 Issue 6, p463 

    Underprescription of potentially useful drugs is widespread among older people and may herald several adverse outcomes. We aimed to review the evidence pertaining to the epidemiology, causes and consequences of underprescribing, as well as recent advances in the development of interventions able...

  • Data-mining law struck down. Carlson, Joe // Modern Healthcare;6/27/2011, Vol. 41 Issue 26, p8 

    The article reports that the U.S. Supreme Court ruled in the case Sorrell v. IMS Health that Vermont legislators violated free speech when they passed a law in 2008 banning drugmakers from using physicians' prescription data for marketing drugs. IMS Health officials argued that restrictions on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics